# SEMA4C as a Relapse Biomarker in Breast Cancer

> **NCT03663153** · — · NOT_YET_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 4200 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** SEMA4C high value follow-up group
- **OTHER:** SEMA4C low value follow-up group

## Key facts

- **NCT ID:** NCT03663153
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-09-01
- **Primary completion:** 2023-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 4200 (ESTIMATED)
- **Last updated:** 2021-10-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03663153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03663153, "SEMA4C as a Relapse Biomarker in Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03663153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*